(Q36471058)

14 August 2017

1 reference

title

Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline (English)

1 reference

14 August 2017

1 reference

9

1 reference

Hans-Christoph Steinhausen

14 August 2017

1

Tobias Banaschewski

0 references

12

Hans-Christoph Steinhausen

0 references

Aribert Rothenberger

10

Aribert Rothenberger

0 references

David Coghill

2

0 references

Philip Asherson

Philip Asherson

5

0 references

Jan Buitelaar

6

Jan Buitelaar

1 reference

14 August 2017

13

Edmund J S Sonuga-Barke

1 reference

14 August 2017

3

Paramala Santosh

1 reference

14 August 2017

4

Alessandro Zuddas

1 reference

14 August 2017

7

Marina Danckaerts

1 reference

14 August 2017

8

Manfred Döpfner

1 reference

14 August 2017

Joseph Sergeant

11

1 reference

14 August 2017

Eric Taylor

14

1 reference

14 August 2017

publication date

5 May 2006

1 reference

European Child & Adolescent Psychiatry

14 August 2017

published in

1 reference

14 August 2017

volume

15

1 reference

14 August 2017

issue

8

1 reference

14 August 2017

page(s)

476-495

1 reference

https://scigraph.springernature.com/pub.10.1007/s00787-006-0549-0

14 August 2017

exact match

0 references

cites work

Treatment of ADHD in children with tics: a randomized controlled trial

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00787-006-0549-0

Comparing the efficacy of medications for ADHD using meta-analysis

21 January 2018

1 reference

12 December 2020

Attention-deficit/hyperactivity disorder in adults: an overview

1 reference

12 December 2020

Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies

1 reference

12 December 2020

Obsessive compulsive disorder

1 reference

12 December 2020

Natural outcome of ADHD with developmental coordination disorder at age 22 years: a controlled, longitudinal, community-based study.

1 reference

12 December 2020

Comparison of acute behavioral effects of sustained-release and immediate-release methylphenidate.

1 reference

12 December 2020

The link between health-related quality of life and clinical symptoms among children with attention-deficit hyperactivity disorder

1 reference

12 December 2020

A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder

1 reference

12 December 2020

Efficacy and safety of Ritalin LA, a new, once daily, extended-release dosage form of methylphenidate, in children with attention deficit hyperactivity disorder

1 reference

12 December 2020

Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: preliminary indications from a secondary analysis of the COMACS study data

1 reference

12 December 2020

Young adult follow-up of hyperactive children: self-reported psychiatric disorders, comorbidity, and the role of childhood conduct problems and teen CD.

1 reference

12 December 2020

A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder

1 reference

12 December 2020

Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder

1 reference

12 December 2020

Pharmacokinetics of SLI381 (ADDERALL XR), an extended-release formulation of Adderall

1 reference

12 December 2020

Pharmacotherapies for attention-deficit/hyperactivity disorder: expected-cost analysis.

1 reference

12 December 2020

Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder

1 reference

12 December 2020

A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents

1 reference

12 December 2020

Nonmedical use of prescription opioids among U.S. college students: prevalence and correlates from a national survey.

1 reference

12 December 2020

A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD

1 reference

12 December 2020

The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies

1 reference

12 December 2020

Psychopharmacology and aggression. I: A meta-analysis of stimulant effects on overt/covert aggression-related behaviors in ADHD.

1 reference

12 December 2020

Methylphenidate bioavailability from two extended-release formulations

1 reference

12 December 2020

Dopamine in drug abuse and addiction: results from imaging studies and treatment implications

1 reference

12 December 2020

A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder

1 reference

12 December 2020

1 reference

12 December 2020

Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: A 4-week, mul

1 reference

12 December 2020

Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies

1 reference

12 December 2020

Pharmacokinetics and Clinical Effectiveness of Methylphenidate

1 reference

12 December 2020

Improvement in health-related quality of life in children with ADHD: an analysis of placebo controlled studies of atomoxetine

1 reference

12 December 2020

Does a morning dose of Methylphenidate Retard reduce hyperkinetic symptoms in the afternoon?

1 reference

12 December 2020

Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults

1 reference

12 December 2020

Does the medicating ADHD increase or decrease the risk for later substance abuse?

1 reference

12 December 2020

Psychometric validation of the child health questionnaire (CHQ) in a sample of children and adolescents with attention-deficit/hyperactivity disorder

1 reference

12 December 2020

Comparative efficacy of two once daily methylphenidate formulations (Ritalin LA and Concerta) and placebo in children with attention deficit hyperactivity disorder across the school day.

1 reference

12 December 2020

Emergence of tics in children with ADHD: impact of once-daily OROS methylphenidate therapy

1 reference

12 December 2020

Comparison of the clinical efficacy of twice-daily Ritalin and once-daily Equasym XL with placebo in children with Attention Deficit/Hyperactivity Disorder

1 reference

12 December 2020

The measurement of health-related quality of life (QOL) in paediatric clinical trials: a systematic review

1 reference

12 December 2020

A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder

1 reference

12 December 2020

ADHD treatment with once-daily OROS methylphenidate: final results from a long-term open-label study

1 reference

12 December 2020

A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD.

1 reference

12 December 2020

The role of stimulants in the treatment of preschool children with attention-deficit hyperactivity disorder

1 reference

12 December 2020

1 reference

12 December 2020

Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings

1 reference

12 December 2020

Effect of methylphenidate formulation for attention deficit hyperactivity disorder on patterns and outcomes of treatment

1 reference

12 December 2020

Long-term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit/hyperactivity disorder: an interim analysis.

1 reference

12 December 2020

Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder

1 reference

12 December 2020

Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder

1 reference

12 December 2020

European clinical guidelines for hyperkinetic disorder -- first upgrade

1 reference

12 December 2020

Varieties of preschool hyperactivity: multiple pathways from risk to disorder

1 reference

12 December 2020

Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type.

1 reference

12 December 2020

Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications

1 reference

12 December 2020

Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders

1 reference

12 December 2020

A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder

1 reference

12 December 2020

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

1 reference

12 December 2020

A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder

1 reference

12 December 2020

A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).

1 reference

12 December 2020

Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial

1 reference

12 December 2020

Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder

1 reference

12 December 2020

Comparative efficacy of once-a-day extended-release methylphenidate, two-times-daily immediate-release methylphenidate, and placebo in a laboratory school setting

1 reference

12 December 2020

10.1007/S00787-006-0549-0

Identifiers

DOI

1 reference

14 August 2017

1 reference